Jaseng Hospital of Korean Medicine   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Seoul Korea, Republic of (1988)

Organization Overview

First Clinical Trial
2014
NCT02196129
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Jaseng Hospital of Korean Medicine | Jaseng Medical Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

hwangryun (1 trial)

sinbaro-3 (1 trial)

Drugs in Phase 1 Trials (1)

bee venom (1 trial)

Drugs in Other Trials (9)

chuna (1 trial)

diclofenac (voltaren) (1 trial)

eucommia (1 trial)

hifenac (1 trial)

loxoprofen (1 trial)

shinbaro (1 trial)

taheebo (1 trial)

talniflumate (1 trial)

tramadol (Ultram) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Low Back Pain (Phase 3)

Radiculopathy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 12